Seres Therapeutics (NASDAQ:MCRB) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday. The firm currently has a $12.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price objective points to a potential upside of 17.65% from the stock’s current price.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Other equities analysts have also recently issued reports about the stock. BidaskClub cut shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Cowen reissued a “buy” rating on shares of Seres Therapeutics in a report on Monday, October 2nd. CIBC began coverage on shares of Seres Therapeutics in a research report on Friday, October 13th. They issued an “outperform” rating and a $19.00 price target on the stock. Oppenheimer began coverage on shares of Seres Therapeutics in a research report on Thursday, October 12th. They issued an “outperform” rating and a $19.00 price target on the stock. Finally, Citigroup began coverage on shares of Seres Therapeutics in a research report on Thursday, October 12th. They issued a “positive” rating and a $19.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the stock. Seres Therapeutics presently has an average rating of “Buy” and a consensus price target of $18.00.

Seres Therapeutics (NASDAQ:MCRB) traded up $0.14 during midday trading on Tuesday, hitting $10.20. 143,307 shares of the stock were exchanged, compared to its average volume of 160,358. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.11. Seres Therapeutics has a one year low of $8.85 and a one year high of $17.42.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.22. The business had revenue of $23.00 million during the quarter, compared to analysts’ expectations of $17.29 million. Seres Therapeutics had a negative net margin of 267.15% and a negative return on equity of 82.11%. The business’s revenue was up 76.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.46) EPS. equities research analysts expect that Seres Therapeutics will post -2.33 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System grew its stake in shares of Seres Therapeutics by 1.1% in the 2nd quarter. California State Teachers Retirement System now owns 36,280 shares of the biotechnology company’s stock worth $410,000 after acquiring an additional 400 shares in the last quarter. Teachers Advisors LLC boosted its position in Seres Therapeutics by 1.2% during the second quarter. Teachers Advisors LLC now owns 38,758 shares of the biotechnology company’s stock worth $438,000 after purchasing an additional 450 shares during the period. Schwab Charles Investment Management Inc. boosted its position in Seres Therapeutics by 0.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 91,543 shares of the biotechnology company’s stock worth $1,035,000 after purchasing an additional 494 shares during the period. Parametric Portfolio Associates LLC boosted its position in Seres Therapeutics by 2.7% during the second quarter. Parametric Portfolio Associates LLC now owns 21,915 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 580 shares during the period. Finally, American International Group Inc. boosted its position in Seres Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 727 shares during the period. Institutional investors own 77.83% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Seres Therapeutics (MCRB) Raised to “Buy” at Zacks Investment Research” was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/10/seres-therapeutics-mcrb-raised-to-buy-at-zacks-investment-research.html.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.